RemeGen Co Ltd is a China-based company engaged in research, development and commercialization of biological drugs. The Company's clinical-stage drug candidates include telitacicept (RC18) used for the treatment of systemic lupus erythematosus, and disitamab vedotin (RC48) used for the treatment of gastric cancer.